20 completed. 20 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 20 |
| Phase 2 | 5 | Completed 5 |
Follow copanlisib: new trials by email Literature Review of copanlisib trials Research Report on copanlisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lung Cancer With Copanlisib and Durvalumab Durvalumab, Copanlisib - Non Small Cell Lung Cancer | Phase 1 | Completed | Zhonglin Hao | 11 | 2021-05-12 | 2025-11-18 |
| Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib - Thyroid Carcinoma, Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2020-06-26 | 2025-09-08 |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Copanlisib, Niraparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2019-04-29 | 2026-07-23 |
| A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma Copanlisib, Ibrutinib - Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2019-03-13 | 2022-12-14 |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer Copanlisib, Nivolumab - Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 48 | 2019-01-17 | 2025-09-16 |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Copanlisib, Nivolumab - Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 | Completed | Bayer | 16 | 2018-10-17 | 2023-10-06 |
| Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics Copanlisib (Aliqopa, BAY80-6946), Metformin - Healthy Volunteers | Phase 1 | Completed | Bayer | 13 | 2018-09-11 | 2020-01-28 |
| Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) Ibrutinib, Copanlisib - Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 18 | 2018-08-23 | 2026-02-09 |
| Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors Rogaratinib (BAY1163877), Copanlisib (BAY80-6946) - Advanced or Metastatic Solid Tumor | Phase 1 | Completed | Bayer | 16 | 2018-07-25 | 2022-07-14 |
| Copanlisib Chinese PK Study Copanlisib (Aliqopa, BAY80-6946) - Lymphoma, Non-Hodgkin | Phase 1 | Completed | Bayer | 13 | 2018-04-27 | 2021-05-19 |
| Copanlisib and Gemcitabine in Relapsed/Refractory PTCL Copanlisib, Gemcitabine - Mature T-Cell and NK-Cell Neoplasm | Phase 1 / Phase 2 | Completed | Chonnam National University Hospital | 28 | 2018-02-01 | 2022-06-10 |
| Study of Copanlisib in Hepatic or Renal Impairment Copanlisib (ALIQOPA, BAY80-6946) - Hepatic Insufficiency, Renal Insufficiency | Phase 1 | Completed | Bayer | 30 | 2017-06-14 | 2021-04-28 |
| Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) Copanlisib, Trastuzumab - HER2 Positive Breast Cancer | Phase 1 | Completed | Cancer Trials Ireland | 26 | 2016-04-01 | 2026-04-13 |
| Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL Copanlisib (BAY80-6946) - Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Completed | Bayer | 25 | 2015-04-21 | 2023-01-20 |
| COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients Copanlisib (BAY80-6946), Itraconazole, Rifampin - Medical Oncology | Phase 1 | Completed | Bayer | 51 | 2014-10-08 | 2020-12-14 |
| Copanlisib Pharmacodynamic Study Copanlisib (BAY80-6946) - Non Hodgkin Lymphoma | Phase 1 | Completed | Bayer | 63 | 2014-08-12 | 2017-06-16 |
| Copanlisib Mass Balance Study Copanlisib (BAY80-6946) - Healthy Volunteers | Phase 1 | Completed | Bayer | 6 | 2014-02-01 | 2014-10-28 |
| Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer Paclitaxel, Copanlisib (BAY80-6946) - Neoplasms | Phase 1 | Completed | Bayer | 55 | 2011-08-24 | 2017-10-11 |
| Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer Copanlisib + Refametinib (BAY86-9766) - Neoplasms | Phase 1 | Completed | Bayer | 64 | 2011-07-01 | 2015-04-17 |
| BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer Copanlisib (Aliqopa, BAY80-6946) - Neoplasms | Phase 1 | Completed | Bayer | 57 | 2009-11-19 | 2017-10-06 |
Lymphoma, Non-Hodgkin (4) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Disease Progression (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hepatic Insufficiency (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Ovarian Neoplasms (1) · Renal Insufficiency (1)
Bayer (12) · Memorial Sloan Kettering Cancer Center (3) · Cancer Trials Ireland (1) · Chonnam National University Hospital (1) · M.D. Anderson Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Zhonglin Hao (1)
United States (13) · Germany (3) · Belgium (2) · Canada (2) · Netherlands (2) · South Korea (2) · China (1) · France (1) · Ireland (1) · Japan (1) · Romania (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Alan L Ho, MD, PhD (1) · Christian Grommes, MD (1) · Connie Batlevi, MD, PhD (1) · Nilofer Azad, MD (1) · Shannon N Westin (1) · Zhonglin Hao, MD (1)
PMID 27672108, PMID 31619463, PMID 32314268, PMID 32379297, PMID 35322287, PMID 37171634, PMID 41528970, PMID 42493490, PMID 5035790
2016 (1), 2018 (1)